semaglutide adverse events by gender in SUSTAIN 6. *On-treatment analysis A1C & Weight Results |

Combine compounded semaglutide with strength workouts to lose fat & preserve muscle

Renal and cardiovascular protection, reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Where testing, COA or supporting documentation is available, it should be checked alongside internal research procurement requirements

PMID: 36341914

Understanding your GLP1R and GIPR pathways through biomarkers can help guide whether lifestyle alone or medical support is appropriate for your weight management goals

However, cardiovascular safety trials in type 2 diabetes patients, the majority presenting cardiovascular disease and excess weight, showed that GLP-1 receptor agonists were indeed capable of decreasing cardiovascular risk